🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 02043Q107
- Market Cap
- Large Cap
Business: Alnylam is a biopharmaceutical company leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Company Contact
- CEO
- Yvonne Greenstreet
- CFO
- Jeff Poulton
- Headquarters
- 675 West Kendall Street, Henri A. Termeer Square Cambridge, MA 02142
- Phone
- 617-551-8200
- Fax
- 617-551-8101
- Investor Relations
- Josh Brodsky · 617-551-8276 · investors@alnylam.com